Industry News
-
Editas Medicine Unveils Promising In Vivo Gene Editing Data for Sickle Cell Disease and Beta Thalassemia, Highlighting HSC-Targeted tLNP Delivery
Jun 12 2025 -
Fidanacogene Elaparvovec, an AAV Gene Therapy, Shows Durable Efficacy and Favorable Long-Term Safety for Hemophilia B
Jun 12 2025 -
BioNTech to Acquire Fellow German mRNA Company CureVac for $1.25 Billion
Jun 12 2025 -
Cabaletta Bio Reports Promising CAR-T Therapy Results Across Multiple Autoimmune Diseases, Plans for Pivotal Trials
Jun 12 2025 -
Spain’s SpliceBio Secures $135M Series B to Advance AAV Gene Therapy Pipeline, Led by Sanofi and Roche
Jun 11 2025 -
Pacira BioSciences Reports Positive Three-Year Data for PCRX-201 Gene Therapy in Knee Osteoarthritis
Jun 11 2025 -
Capsida Biotherapeutics Receives FDA IND Clearance for CAP-003, a Novel AAV Gene Therapy for Parkinson’s Disease with GBA Mutations
Jun 11 2025 -
Nuevocor Receives FDA IND Clearance for NVC-001, an AAV Gene Therapy for LMNA-Related Dilated Cardiomyopathy
Jun 10 2025 -
ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for AAV VG801
Jun 09 2025